Video

Dr. Atkinson on Novel Combinations in Melanoma

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses novel combinations for the treatment of patients with melanoma.

Victoria Atkinson, MD, medical oncologist, Princess Alexandra Hospital, University of Queensland, discusses novel combinations for the treatment of patients with melanoma.

According to Atkinson, there are many novel ideas and combinations including talimogene laherparepvec (T-VEC; Imlygic) and injecting plasmas.

Additionally, the combination of LAG3 and PD-1 will have phase III results released early next year, explains Atkinson. Other combinations include IDO inhibitors with PD-1, which has potential to improve response and reduce toxicity.

Related Videos
Alan Tan, MD, genitourinary oncology and melanoma specialist, Vanderbilt-Ingram Cancer Center; associate professor, medicine, Division of Hematology Oncology, Vanderbilt University Medical Center
Bartosz Chmielowski, MD
Raza Hoda, MD, FASCP
Armin Ghobadi, MD, professor, medicine, Oncology, Section of Bone Marrow Transplant; clinical director, Center for Gene and Cellular Immunotherapy, Siteman Cancer Center, Washington University
Timothy S. Fenske, MD, MS
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis